HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine.
نویسندگان
چکیده
Title HBV reactivation in malignant lymphoma patients treated with rituximab and bendamustine Author(s) Tsutsumi, Yutaka; Ogasawara, Reiki; Miyashita, Naohiro; Tanaka, Junji; Asaka, Masahiro; Imamura, Masahiro Citation International Journal of Hematology, 95(5): 588-591 Issue Date 2012-05 DOI Doc URL http://hdl.handle.net/2115/49380 Right The final publication is available at www.springerlink.com Type article (author version) Additional Information File Information IJH95-5_588-591.pdf
منابع مشابه
Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma.
Reactivation of hepatitis B virus (HBV) has been reported not only in HBsAg-positive patients undergoing systemic chemotherapy, but also in a proportion of HBsAg-negative patients with HBc antibody and/or HBs antibody. Recently, rituximab-plus-steroid combination chemotherapy (R-CHOP, etc.) has been identified as a risk factor for HBV reactivation in HBsAg-negative patients with malignant lymph...
متن کاملHBV reactivation in a HBsAg-negative patient with multiple myeloma treated with prednisolone maintenance therapy after autologous HSCT
Hepatitis B virus (HBV) reactivation has previously occurred in hepatitis B surface antigen-negative patients with malignant lymphoma who received rituximab-based combination chemotherapy. However, few reports have described cases of HBV reactivation in patients with multiple myeloma thus far. We report a case of HBV reactivation in a patient with multiple myeloma treated with chemotherapy, aut...
متن کاملRetrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier.
BACKGROUND In surface antigen of hepatitis B virus (HBsAg)-positive carrier for anticancer treatment of malignant lymphoma, it is well recognized that reactivation of hepatitis B virus (HBV) occasionally occurs. However, there have been only a few studies of HBV reactivation in serum HBsAg-negative and hepatitis B core antigen (HBcAb)-positive occult HBV carriers. We looked at both retrospectiv...
متن کاملFulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.
We report a case of a precore mutant hepatitis B virus (HBV) reactivation in a patient with follicular lymphoma who was treated simultaneously with chemotherapy (cyclophosphamide, vincristine and prednisone) and rituximab, occurred five months after the end of therapy. Despite lamivudine therapy, she died because of fulminant hepatitis. This case illustrates the possibility of late reactivation...
متن کاملHepatitis B Reactivation with Novel Agents in Non-Hodgkin’s Lymphoma and Prevention Strategies
Hepatitis B virus (HBV) infection remains an endemic disease in most parts of the world despite available prophylactic vaccines. Non-Hodgkin's lymphoma is the most common hematological malignancy, and certain patients undergoing therapy are at increased risk of HBV reactivation. Rituximab, a monoclonal antibody, is well studied in HBV reactivation, but newer agents have been implicated as well....
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- International journal of hematology
دوره 95 5 شماره
صفحات -
تاریخ انتشار 2012